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ABSTRACT
STUDY OF CONTROLLED RELEASE OF DAPSONE FROM MODIFIED
MONTMORILLONITE AND POLYMER MATRICES
by
Jia Fan
This thesis focuses on the controlled release system of Dapsone (DAP) as the Active
Pharmaceutical Ingredient (API) intercalated into sodium montmorillonite (MMT-Na+)
and their combination with an anionic copolymer (Eudragit® S100). The effects of the
excipients on the API dissolution rate were studied from their release profile in simulated
intestinal fluid (pH=7.4) at 37±0.5°C. In the first part of the research, ionizable Dapsone
was intercalated in the interlayers of MMT-Na+ to produce a nanohybrid. In the second
part of the research, the nanohybrid was melt dispersed in the polymer to produce ternary
(API/ Clay/ Polymer) composites. For comparison, API-polymer solid dispersions were
prepared by melt mixing in the absence of nanoclay.
The intercalated compound was characterized by X-ray diffraction (XRD),
Fourier transform infrared (FT-IR) spectroscopy, and themogravimetric analysis (TGA).
The basal spacing of montmorillonite increased from 1.17nm to 1.55nm. The in vitro
release experiments revealed that Dapsone was steadily released from MMT. In the
second part of the research, an API-polymer miscible system was prepared by melt
mixing. In agreement with solubility parameter differences, Dapsone exists in an
amorphous state in the polymer matrix. The API-modified clay was dispersed in the
polymer to form a ternary system, in which the API showed a more controlled release
profile due to the presence of the nanoclay.

STUDY OF CONTROLLED RELEASE OF DAPSONE FROM MODIFIED
MONTMORILLONITE AND POLYMER MATRICES

by
Jia Fan

A Thesis
Submitted to the Faculty of
New Jersey Institute of Technology
In Partial Fulfillment of the Requirements for the Degree of
Master of Science in Engineering
Otto H. York Department of
Chemical, Biological and Pharmaceutical Engineering

January 2011

APPROVAL PAGE
STUDY OF CONTROLLED RELEASE OF DAPSONE FROM MODIFIED
MONTMORILLONITE AND POLYMER MATRICES
Jia Fan

Dr. Marino Xanthos, Thesis Advisor
Professor of Chemical, Biological and Pharmaceutical Engineering, NJIT

Date

Dr. Laurent Simon, Committee Member
Date
Associate Professor of Chemical, Biological and Pharmaceutical Engineering, NJIT

Dr. Ecevit A. Bilgili, Committee Member
Date
Assistant Professor of Chemical, Biological and Pharmaceutical Engineering, NJIT

BIOGRAPHICAL SKETCH

Author:

Jia Fan

Degree:

Master of Science

Date:

January 2011

Undergraduate and Graduate Education:
•

Master of Science in Chemical Engineering,
New Jersey Institute of Technology, Newark, NJ, 2011

•

Bachelor of Science in Polymer Science & Engineering,
Jilin Institute of Chemical Technology, Jilin, P. R. China, 2008

Major:

Chemical Engineering

In memory of my little cousin – Amy Fan

v

ACKNOWLEDGMENT

First, I would like to acknowledge my advisor, Professor Marino Xanthos for his
professional guidance, kind encouragement and financial support throughout this research.
He also gave me many opportunities to enlarge my vision in my research area. His
significant efforts in this project are highly appreciated and I will never forget this help.
I would like to thank my Committee members, Professor Laurent Simon and
Professor Ecevit A. Bilgili for their advice and priceless support.
I would like to express my profound gratitude to my senior friend, Jin Uk Ha,
who has already been back to Korea, but his invaluable assistance with my research
really led me to succeed in lab experiments.
Moreover, I am grateful to my parents, my grandparents, my uncle’s family and
my girlfriend for their endless support during my graduate studies.

vi

TABLE OF CONTENTS

Chapter

Page

1 INTRODUCTION……............................………………..……………………...….

1

2 LITERATURE SURVEY.....……………………….……………………………….

3

2.1 Compounds of Nanoclays with APIs……………….....……………………..….

3

2.2 Compounds of Polymers with APIs……………………………………………..

6

2.3 Compounds of Polymers with API-Intercalated Clays…………………...……..

10

3 EXPERIMENTAL…. ………………………………………………………………

13

3.1 Materials…………………………………... ………………………………...…

13

3.1.1 Active Pharmaceutical Ingredient…………………………………..…....

13

3.1.2 Cationic Nanoclay………..……………………………………………....

14

3.1.3 Polymer Excipient……………………………………………………......

15

3.1.4 Plasticizer………………………………………………………………...

16

3.2 Sample Preparation……………………………………………………………..

16

3.2.1 Preparation of DAP Functionalized Clay………………………………..

16

3.2.2 Preparation of Eudragit®S100/DAP and Eudragit® S-100/DAP/Clay
Compounds by Melt Mixing……………………………………………..

17

3.3 Characterization………………………………………………………………...

17

3.3.1 Fourier Transform Infrared (TF-IR) Spectrophotometry………………...

17

3.3.2 Wide Angle X-Ray Diffraction (WXRD)……………………………......

17

3.3.3 Thermogravimetric Analysis (TGA)………………….……………….…

18

3.3.4 Differential Scanning Calorimetry (DSC)…………..……………..…......

18

vii

TABLE OF CONTENTS
(Continued)
Chapter

Page

3.3.5 Scanning Electron Microscopy (SEM)…………………………..………

18

3.3.6 Energy Dispersive X-Ray Analysis (EDX)……..……………………….

19

3.3.7 Elemental Analysis……………………………………………………….

19

3.3.8 Dissolution Test and UV-Vis Analysis…………………………………..

19

4 DISCUSSION...…………….…………………………………………….………….

20

4.1 Results on Clay Modified with Dapsone……………………………………......

20

4.1.1 FTIR Analysis……………………………………………………………

20

4.1.2 XRD Analysis…………………………………………………………….

21

4.1.3 Thermal Analysis…………………………………………………………

23

4.1.4 Quantitative Analysis of MMT-DAP…………………………………….

24

4.1.5 Dissolution Test…………………………………………………………..

25

4.2 Results on DAP Compounded with Eudragit®S100…………………………….

26

4.2.1 Thermal Analysis…………………………………………………………

26

4.2.2 XRD Analysis…………………………………………………………….

28

4.2.3 Morphology………………………………………………………………

29

4.2.4 Dissolution Test…………………………………………………………..

31

4.3 Results on DAP modified Clay Compounded with Eudragit®S100.………...….

33

4.3.1 Thermal Analysis…………………………………………………………

33

4.3.2 XRD Analysis…………………………………………………………….

35

4.3.3 Morphology………………………………………………………………

36

viii

TABLE OF CONTENTS
(Continued)
Chapter

Page

4.3.4 Dissolution Test…………………………………………………………..

41

5 CONCLUSIONS………………………………………………………………….…

43

APPENDIX A CALCULATION OF API CONTENT IN NANOCLAY …………….

45

APPENDIX B CALCULATION OF SOLUBILITY PARAMETERS…………..……

46

APPENDIX C INTERCALATION STUDY…………………………………………..

48

REFERENCES ………………………………………………………………………....

56

ix

LIST OF TABLES

Table
4.1

Page

Results of MMT-DAP Elemental Analysis……………………………..………..

25

B.1 Hildebrand Solubility Parameters of Dapsone Groups…………………………...

46

B.2 Hildebrand Solubility Parameters of Eudragit® S100 Groups……………………

46

C.1 Abbreviations of MMT-Na+ Samples Modified with Dapsone………………..…

48

x

LIST OF FIGURES

Figure

Page

2.1

Amorphous solid solution……..………………..…………………………..…….

6

3.1

Chemical structure of Dapsone…………………………………………………...

13

3.2

Molecular structure of MMT-Na+…………………………………….…………..

14

3.3

Chemical structure of Eudragit® S-100…………………………………….……..

15

3.4

Chemical structure of triethyl citrate……………………………………………..

16

4.1

FTIR results of (a) Dapsone (DAP), (b) MMT-DAP, and (c) MMT-Na+………..

21

4.2

XRD results of (a) Dapsone, (b) MMT-Na+, and (c) MMT-DAP………………..

22

4.3

TGA results of (a) MMT-Na+, (b) MMT-DAP, and (c) Dapsone………………..

23

4.4

DSC results of MMT-Na+, MMT-DAP, and Dapsone…………………………...

24

4.5

Dissolution results in simulated intestinal fluid (phosphate buffer pH=7.4) of
(a) Dapsone and (b) MMT-DAP………………………………………………….

25

TGA results of (a) Dapsone, (b) Eudragit®S100, (c) TEC, (d) Eudragit®S100/
20wt% TEC, (e) Eudragit®S100/ 20wt% TEC-5wt% DAP, and (f)
Eudragit®S100/ 20wt% TEC-10wt% DAP………………………………………

27

Tg of (a) Eudragit®S100, (b) Eudragit®S100/ 20wt% TEC, (c) Eudragit®S100/
20wt% TEC-5wt% DAP, and (d) Eudragit®S100/ 20wt% TEC-10wt% DAP…...

28

XRD results of (a) Eudragit®S100/ 20wt% TEC, (b) Eudragit®S100/ 20wt%
TEC-10wt% DAP, (c) Eudragit®S100/ 20wt% TEC-5wt% DAP, and (d)
Dapsone…………………………………………………………………………...

29

Polarized optical microscopy image of Eudragit®S100/ 20wt% TEC-10wt%
DAP……………………………………………………………………………….

30

4.10 SEM image of Eudragit®S100/ 20wt% TEC-10wt% DAP (left) and EDX sulfur
mapping image of the same region (right)………………………………………..

30

4.6

4.7

4.8

4.9

xi

LIST OF FIGURES
(Continued)
Figure

Page

4.11 Dissolution results in simulated intestinal fluid (phosphate buffer pH=7.4)
of (a) Dapsone, (b) Eudragit®S100/ 20wt% TEC-5wt% DAP and
(c) Eudragit®S100/ 20wt% TEC-10wt% DAP…………………………………...

31

4.12 TGA results of (a) Eudragit®S100/ 20wt% TEC, (b) Eudragit®S100/ 20wt%
TEC-10wt% DAP, (c) Eudragit®S100/ 20wt% TEC-10wt% (DAP/MMT-Na+
physical mixture), and (d) Eudragit®S100/ 20wt% TEC-10wt% (MMT-DAP
hybrid)…………………………………………………………………………….

33

4.13 Tg of (a) Eudragit®S100, (b) Eudragit®S100/ 20wt% TEC-10wt% DAP, (c)
Eudragit®S100/ 20wt% TEC-10wt% (DAP/MMT-Na+ physical mixture), and
(d) Eudragit®S100/ 20wt% TEC-10wt% (MMT-DAP hybrid)…………………..

34

4.14 XRD results of (a) Eudragit®S100/ 20wt% TEC-10wt% DAP, (b) MMT-Na+,
and (c) MMT-DAP, (d) Eudragit®S100/ 20wt% TEC-10wt% (MMT-DAP
hybrid), and (e) Eudragit®S100/ 20wt% TEC-10wt% (DAP/MMT-Na+ physical
mixture)…...............................................................................................................

35

4.15 SEM image of 10wt% DAP/MMT-Na+ physical mixture in Eudragit®S100 and
EDX mappings of elements aluminum, silicon, sodium and sulfur……………...

37

4.16 SEM image of 10wt% DAP/MMT-Na+ physical mixture in Eudragit®S100 and
EXD Mapping of aluminum (left) and silicon (right)…………………………….

38

4.17 Magnified SEM images of circle shown in Figure 4.16………………………….

39

4.18 SEM image of 10wt% MMT-DAP hybrid in Eudragit® S100 and EDX
mappings of elements aluminum, silicon and sulfur……………………………..

40

4.19 Dissolution results in simulated intestinal fluid (phosphate buffer pH=7.4)
of (a) Eudragit®S100/ 20wt% TEC-10wt% DAP, (b) Eudragit®S100/ 20wt%
TEC-10wt% (DAP/MMT-Na+ physical mixture), and (c) Eudragit®S100/
20wt% TEC-10wt% (MMT-DAP hybrid)……………………………….……….

41

C.1 XRD results of Dapsone, MMT-Na+, (a) 2xRT24h-N and (b) 2xRT24h………...

49

xii

LIST OF FIGURES
(Continued)
Figure

Page

C.2 TGA results of Dapsone, MMT-Na+, (a) 2xRT24h-N and (b) 2xRT24h………...

50

C.3 Weight loss of MMT-DAP hybrids soaked in different times……………………

51

C.4 XRD results of (b) 2xRT24h, (c) 2xRT15h, (d) 2xRT3h and (e) 2xRT1h……….

52

C.5 Intercalation of Dapsone at different temperatures……………………...………..

53

C.6 XRD results of (d) 2xRT3h, (e) 2xRT1h, (f) 2x60oC3h and (g) 2x60oC1h………

54

C.7 TGA results of (e) 2xRT1h and (h) 1xRT1h ……………………………..……...

54

xiii

CHAPTER 1
INTRODUCTION

Drug bioavailability implies the extent and rate at which a drug becomes available in the
general circulation. Dissolution of the drug in the aqueous gastric and intestinal
surroundings is a requirement for its absorption following oral administration.1 Based on
their solubility and intestinal permeability characteristics, drug substances have been
classified into four categories according to the Biopharmaceutics Classification System
(BCS) proposed by Amidon et al.2
BCS class II drugs exhibit low solubility and high permeability characteristics.
Their oral absorption is mostly governed by in vivo dissolution3; solubility behavior is a
key determinant for the oral bioavailability of these drugs. 4 Dapsone (DAP), a symmetric
drug with two identical aromatic amine groups, belongs to the BCS class II.5 To improve
oral bioavailability of such poorly water soluble drugs, different techniques can be used,
such as salt formation, particle size reduction and solid dispersion.6 In this thesis, three
different types of drug delivery systems prepared by different methods are investigated.
Montmorillonite (MMT) is a biocompatible natural clay mineral that has already
found uses in pharmaceutical applications. Its layer structure has a superior capability to
intercalate large molecules into the interlayer space. In this research, the intercalation of
Dapsone into montmorillonite as drug carrier was firstly investigated. Generally,
intercalation of API in MMT is a fast process, due to the occurrence of an ion exchange
reaction between the interlayer Na+ ions and cationic API molecules.7 Dapsone release
from the MMT-DAP hybrid in simulated intestinal fluid was subsequently investigated.

1

2
Preparation of an amorphous solid dispersion in polymers is another effective way
of increasing the dissolution rate of poorly water-soluble drugs, which is also the purpose
of the second part of this research. Hot melt extrusion (HME) is currently being
investigated for applications in pharmaceutical dosage development to produce
polymer/API solid dispersions;8 it is a solvent free continuous process that can lead to
fewer processing steps. In this study, a batch mixer was used for the small scale melt
mixing process since it has two counter-rotating screws, which impart mixing similar to
that generated by twin-screw extruders.9 Eudragit® S100, an amorphous copolymer
showing complete dissolution at pH greater than 7, was selected in this investigation. By
calculating solubility parameters, the miscibility of Dapsone in the polymer matrix can be
predicted and subsequently confirmed by the morphology of the compounds.
The last part of this research refers to a novel delivery system containing MMTDAP hybrid dispersed in Eudragit® S100 matrix by the melt mixing process. Compared
with the polymer/API system, this ternary system is anticipated to achieve a more
controllable and/or sustained API release pattern since the API intercalated nanoclay
combined with the slow diffusion of the polymer would result in a more tortuous path for
API release. This has been demonstrated in an equivalent system containing an anionic
clay-anionic API nanohybrid, with or without a polymer.10 In order to understand and
identify potential pharmaceutical applications of this ternary system for controlled drug
delivery, a physical mixture of MMT and Dapsone was also mixed with Eudragit® S100
as a comparison. Furthermore, miscibility and thermal stability of the polymer/hybrid
mixture produced by intercalation or mechanical blending are investigated.

CHAPTER 2
LITERATURE SURVEY

2.1 Compounds of Nanoclays with APIs
Clay minerals have large specific surface area and exhibit good adsorbability, ion
exchange capacity, standout adhesive ability and drug carrying capability.11 Clays play an
important role in pharmaceutical products used as excipients and active agents.
Hydrotalcite (HT), also known as layered double hydroxides (LDH), is an anionic
nanoclay with positively charged layers and charge-balancing anions in the interlayer
space.12 Montmorillonite (MMT) is one mineral of the smectite group, composed of silica
tetrahedral sheets layered between alumina octahedral sheets. The imperfection of the
crystal lattice induces a net negative charge that leads to the adsorption of alkaline earth
metal ions in the interlayer space.7 The clays intercalated by API as drug carrier have
received considerable attention in recent years. Some commercialized pharmaceutical
products using clay minerals as excipients are currently sold in the market.12
Zhang et al.13 investigated the intercalation of Captopril into the interspacing of
LDH followed by its release which was carried out in a simulated gastrointestinal and
intestinal fluid at pH 4.60 and 7.45 as release medium. The intercalation of the anionic
clay was confirmed by TG-DTA, XRD and FT-IR. Approximately 31.11% of Captopril
was intercalated into the interspace, and as result the interlayer distance increased from
0.48 nm to 1.462 nm. In vitro drug release studies showed that the release rate and release
percentages of API from the hybrid were markedly decreased with increasing medium pH
value.
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Xia et al.14 intercalated several anionic antihypertensive drugs including Enalpril,
Lisinopril, Captopril and Ramipril into Zn/Al layered double hydroxides; the
intercalations were verified by observing XRD peak shifting to low 2 angles indicating
a swelling of the layers due to the drug molecules. Calculated drug loading in the Zn-Al
LDHs interspace ranged from 28.79% to 47.22%. The sustained-release profiles of API
from drug-LDHs followed the Higuchi’s square root law because the concentration of
API release increased with the square root of time.
Controlled drug release of ibuprofen (IBU) intercalated in montmorillonite was
investigated by Zheng et al.15 According to XRD and TGA results, the basal spacing of
montmorillonite increased from 1.25 nm to 1.57 nm and the decomposition temperature
of intercalated IBU was increased to 471°C. From FT-IR results, several new absorption
bands were recognized and indicated that IBU interacts strongly with the montmorillonite
layers. The in vitro release experiment showed that the release of IBU from IBU/MMT
hybrid was affected by the pH value. The release rate in simulated intestinal fluid
(pH=7.4) was noticeably higher than that in simulated gastric fluid (pH=1.2).
Lin et al.16 studied purified montmorillonite intercalated with 5-fluorouacil (5-FU)
as drug carrier. The optimum condition for 5-FU/montmorillonite preparations is 1.185%
of 5-FU as initial concentration under a pH value of 11.6 at a temperature of 80°C and a
soaking time of 2h. From FTIR, TGA and XRD data, 5-FU has been confirmed to
successfully intercalate into the interlayers of montmorillonite both by free surface
adsorption and sodium ion replacement. The composite of 5-FU/montmorillonite is
expected to achieve in situ release for colorectal cancer therapy in future applications.
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Joshi et al.7 reported that the intercalation of timolol maleate (TM) into MMT was
a rapid process and equilibrium was attained within 1h. The maximum amount of TM
intercalated into MMT is 217 mg/g MMT within 1h at pH 5.7 and 30°C. Intercalation of
TM into MMT depends on the pH of the interaction medium. XRD patterns of the hybrid
material showed an increase in the d-spacing, conforming to the intercalation of TM into
the interlayer of MMT. TG-DTA of MMT-TM showed a sharp weight loss at about
200°C due to decomposition of exchanged TM. In vitro release study showed that about
43 and 48% of TM was released from the MMT-TM hybrid in simulated gastric fluid (pH
1.2) and intestinal fluid (pH 7.4), respectively. These studies indicate that MMT can be
used as the sustained release carrier of TM in oral administration.
A study on the controlled release and antibacterial activity of chlorhexidine (CA)
intercalated in montmorillonite was reported by Meng et al.17 The XRD patterns of
CA/MMT showed an expansion in the clay basal spacing indicating that CA was
intercalated into the interlayer of MMT. In a drug release study of CA/MMT, CA was
burst released for the initial 24 hours and then was continuously released over 72 hours.
Therefore, MMT was suggested as an advanced drug delivery carrier with controlled
release characteristics. The antibacterial activity of CA/MMT was evaluated by the
inhibitory zone tests. The results showed that CA/MMT composites had broad-spectrum
antibacterial capability.
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2.2 Compounds of Polymers with APIs
Binary polymer-API systems are usually desired to be miscible if, after a given
processing operation such as hot melt extrusion or solvent evaporation, only one glass
transition temperature exists. The amorphous form of API may provide enhanced
solubility, dissolution rate, and bioavailability but will also potentially crystallize over
time.18 More recently, many polymers including polyvinylpyrrolidone (PVP),
polyethyleneoxide (PEO), Eudragit (acrylates), polyethylene glycol (PEG) and cellulose
derivatives have been reported for being used as drug carriers. These polymers are
particularly likely to form amorphous solid solutions as the polymers are present in the
form of amorphous polymer chain networks (Figure 2.1). In addition, the API molecules
as solutes can plasticize the polymer, leading to a reduction in its glass transition
temperature. With respect to the HME technique, Forster et al.8 indicated that an
important variable in the melt mixing process is the selection of a temperature that fully
plasticizes the polymer without causing chemical decomposition of the API.

Figure 2.1 Amorphous solid solution.4
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In order to select suitable combinations of polymers and APIs to form an
amorphous solid solution, the miscibility in solid solution can be predicted by comparing
the solubility parameters (δ) of polymers and APIs. The solubility parameter is defined as
the square root of the cohesive energy density as described by equation19:

δ  (EV / Vm )0.5

(2.1)

where EV represents the energy of vaporization and Vm is the molar volume of the
material. The Hildebrand solubility parameters of the materials were calculated with the
method proposed by Fedors20:

δ  ( ei /  vi )0.5

(2.2)

where ei and vi are the additive atomic and group contributions for the energy of
vaporization and the molar volume. Compounds with similar values for solubility
parameters are likely to be miscible. This is because the energy of mixing within the
components is balanced by the energy released by interaction between the components 21.
Greenhalgh22 demonstrated that compounds with δ<7.0MPa1/2 are likely to be
1/2
miscible while compounds with δ>10.0MPa
are likely to be immiscible.


Sun et al.6 studied the effects of nimodipine (NMD) on Eudragit® E100
(aminoacryl methacrylate copolymer) and Plasdone® S630 (vinyl pyrrolidone-vinyl
acetate copolymer) prepared by hot melt extrusion. X-ray diffraction and DSC analysis
showed that Eudragit® E100 and Plasdone® S630 were compatible with NMD in the solid
dispersion system. HME was applied to disperse drugs to a molecular level in a given
matrix. Compared with the pure drug and physical mixture, the dissolution of NMD was
enhanced dramatically since the API was effectively transformed into an amorphous state.
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Albers et al.23 studied the poorly water-soluble drug celecoxib blended with a
polymethacrylate carrier by hot-melt extrusion. XRD and DSC measurements indicated
the formation of a glassy solid solution, where the drug is molecularly dispersed in the
carrier. The amorphous state of the glassy solid solution could be maintained during the
exposure to a mechanical stress in a milling process. Two mechanisms of drug release
from solid dispersions were reviewed. Carrier-controlled dissolution predominates when
the API release is dependent on the properties of the carrier. If the API release is
dependent on the API properties it is called API-controlled dissolution. Solid-state
properties and SEM images of extrudates after dissolution indicated that a carriercontrolled dissolution occurred in this system. Furthermore, recrystallization could be
inhibited by the external addition of hydroxypropyl methylcellulose (HPMC) to the
dissolution medium.
Mididoddi et al.24 used hydroxypropyl cellulose (HPC) and poly(ethylene oxide)
as polymer carrier and demonstrated that drug loaded films containing up to 20%
ketoconazole were successfully prepared by HME processing. DSC, SEM and XRD
techniques indicated that melt cooled mixtures of the drug and the two polymers were
amorphous. The bioadhesive properties of these films were investigated on the human
nail (ex vivo) using a Texture Analyzer®, which could be influenced by instrument
variables such as contact force, contact time and speed of probe removal from the tissue.
The peak adhesion force (PAF) is the maximum force required to remove the extruded
film from the human nail and the work of adhesion was determined from the area under
the force-distance curve (AUC). In this study, higher PAF and AUC was achieved
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indicating strong adhesive bonds between the HME film and nail, and this film would be
relevant as potential dosage form for onychomycosis and other fungal infections.
Hot-melt extruded tablets with enteric and sustained-release properties were
prepared by Yang et al.25 using ketoprofen as a model drug and Eudragit® L100 as the
carrier. Ketoprofen homogeneously dispersed in the polymer matrix in a non-crystalline
state, and this was confirmed by DSC, XRD and SEM analysis. The drug release
percentage was below 3% in 0.1M HCl and a sustained release for 6 to 12 hours was
obtained with the tablets prepared by direct cutting of the extrudates and by compressing
the pulverized extrudates, while no enteric and sustained-release properties were
exhibited by the physical mixture tablets. For the cut tablets, the drug was released
according to the erosion mechanism, whereas in the extruded tablets the release property
was controlled by the erosion and diffusion mechanisms simultaneously.
Kakran et al.26 used an evaporative precipitation of nanosuspension (EPN)
method to fabricate composite particles of a poorly water-soluble antimalarial drug,
artemisinin, with polyethylene glycol (PEG). The DSC and XRD studies suggested that
the crystallinity of the EPN-prepared artemisinin decreased with increasing polymer
concentration, which improved the dissolution of the artemisinin particles. The phase
solubility of artemisinin increased linearly with increasing PEG concentration and
temperature. The artemisinin/PEG composite particles produced by the EPN method have
good potential for improved drug delivery in much smaller doses than with commercial
preparation methods.
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2.3 Compounds of Polymers with API-Intercalated Clays
Polymer-API intercalated nanoclay composites have recently been investigated for
controlled drug release applications. Compared with polymer-API system, the
compounds containing API modified clay minerals provide an advantageous drug
delivery system. Because the release of API intercalated nanoclay is potentially
controllable in pH dependent polymers as host matrices, these new materials have a great
potential in the pharmaceutical field. There are only few reports on the API
functionalized nanoclay compounded with polymer, especially using hot melt mixing
process.
Ha10 reported this novel delivery system produced by hot melt mixing. Eudragit®
E-100 containing 10 wt% sodium diclofenac (DIK) modified hydrotalcite was prepared
by batch mixer at 50 rpm and 130°C for 5 min. The XRD patterns of this ternary system
showed crystalline peaks but were not same as those when Eudragit® E-100 was
compounded with DIK; this may indicate that the DIK/clay still maintains its crystalline
structure and no API was released during melt mixing. According to the morphology
study that followed, Eudragit® E-100 mixed with DIK/clay showed better dispersion
compared to the direct mixing of Eudragit® E-100 and DIK. Furthermore, DIK released
from Eudragit® E-100-DIK/clay compound showed 10% higher solubility as compared to
the polymer/API binary system. This could be attributed to the DIK present in amorphous
state in the clay interlayer space.
Joshi et al.27 illustrated the suitability of montmorillonite as a drug delivery carrier,
by developing clay/API composite of ranitidine hydrochloride (RT) intercalated in MMT.
The prepared MMT-RT hybrid was coated with cationic polymer Eudragit ® E-100 by oil-
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in-water solvent evaporation method. The interlayer spacing of 16.8Å for MMT-RT
determined by XRD, suggested a vertical orientation of the RT cation in a bilayer
arrangement. According to FT-IR analysis, the characteristic bands of RT shifted in the
hybrid material signifying the strong interaction of RT into the MMT layers. In vitro
release showed that 51% of RT was released from MMT-RT hybrid in gastric fluid of pH
1.2, which was greatly enhanced by coating with Eudragit® E-100. The release of RT
from the hybrid followed the parabolic diffusion mechanism.
Li et al.28 used an anti-inflammatory drug, fenbufen, intercalated with LDHs as
the core followed by coating with Eudragit® S-100. The dissolution profile showed a slow
release of the intercalated drug, but only 67% of the drug was liberated after 5 h at pH 7.4.
This suggests that complete dissolution of the polymer and de-intercalation of fenbufen
from the LDH may be inhibited by an interaction between the carboxylate groups of the
polymer and the surface of the LDH.
Han et al.29 reported that the intercalation of Paraquat (PQ), the cationic herbicide
as a model compound used in the agricultural field, into the montmorillonite layers could
be achieved by the ion exchange reaction and the simple solid state reaction, providing
the controlled release functionality. According to the solid state reaction method, the
mixture of Paraquat and MMT-Na+ was ground under 150°C for 2 h. Compared with the
hybrid prepared by the conventional solution reaction, there was no distinct difference in
the XRD patterns, which showed the same expansion of basal spacing indicating that the
PQ molecules were successfully intercalated into the MMT layers by two different
methods. Similar FT-IR spectra gave further supporting evidence. In order to achieve the
pH dependent release of the intercalated PQ molecules, the PQ-MMT complex was
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coated with cellulose acetate phthalate (CAP). The ternary system exhibited a strongly
suppressed PQ release in the acidic pH domain, while an enhanced PQ release at the
neutral pH range.
Three different smectite clays (laponite XLG, saponite, and montmorillonite)
intercalated by donepezil were reported by Park et al.30 Powder XRD patterns, TG
profiles, and FTIR spectra confirmed that donepezil molecules were well stabilized in the
interlayer space of the clays. The thermal stability of the API molecules was also
improved after the hybridization. In order to improve dispersibility and formulate a
donepezil delivery system with an improved release rate, the hybrids were coated with
Eudragit® E-100 through spray drying. The release profile of Eudragit® E-100 coated
hybrid showed a biphasic release pattern, being consisted of a burst and slow release.
This suggested that some donepezil molecules encased in clay materials could be
replaced by Eudragit® E-100 during the coating process.

CHAPTER 3
EXPERIMENTAL

3.1 Materials
3.1.1 Active Pharmaceutical Ingredient
The active pharmaceutical ingredient (API) used in this study is 4, 4’-Diaminodiphenyl
Sulfone (Dapsone) purchased from Sigma-Aldrich. Its structural formula is shown in
Figure 3.1.

Figure 3.1 Chemical structure of Dapsone.

Dapsone (DAP) is a synthetic derivative of diamino-sulfone with antiinflammatory and anti-parasitic properties; it has been

used to treat leprosy and

dermatitis for many years.31 It is a yellowish white, odorless crystalline powder with
molecular weight of 248.31 g/mol and melting point (Tm) of 175.5°C.
Because of the two ionizable amino groups, Dapsone has two pKa values (1.3 and
2.4), and it is expected to be cationic API in its ionized state. Therefore, ionized dapsone
could intercalate into the interspacing of a cationic nanoclay through cationic exchange
reactions. Dapsone was selected for a miscible API-polymer system since its solubility
parameter differs by less than 7.5 MPa1/2 from that of the Eudragit® S-100 polymer.
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3.1.2 Cationic Nanoclay
The cationic nanoclay used in this work is Sodium Montmorillonite (trade name:
Cloisite®Na+, CAS# 1318-93-0) obtained from Southern Clay Products, Inc (Figure 3.2).
It is a hydrated aluminum silicate with sodium ions as the predominant exchangeable
cation (Cationic Exchange Capacity, CEC = 92.6meq/100g). The chemical formula is
Na0.33Al2Si4O10(OH)2 ·nH2O, and the basal spacing is 11.7Å.

Figure 3.2 Molecular structure of MMT-Na+. 32
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3.1.3 Polymer Excipient
An amorphous anionic copolymer (Eudragit® S-100) based on methacrylic acid and
methyl methacrylate (1:2) with pKa value of 6.66 ± 0.05 33 donated by Evonik Industries
(Piscataway, NJ) (Figure 3.3), was used as the excipient of the API and the API modified
clay.

Figure 3.3 Chemical structure of Eudragit® S-100.
Eudragit® S-100 dissolves in water above pH 7.0, and is expected to be used in
ileum and colon targeted delivery. The polymer has a reported Tg of 172°C

34

and

maximum processing temperature of 186°C. Considering the narrow range between Tg
and processing temperature, a pre-plasticization step was necessary to avoid
decomposition of Eudragit® S-100 during melt processing. Suitable plasticizers including
triethyl citrate, dibutyl sebacate, polyethylene glycol and propylene glycol can reduce the
polymer’s glass transition temperature and melt viscosity.
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3.1.4 Plasticizer
Triethyl citrate (TEC) (Sigma-Aldrich) is a hydrophilic plasticizer used in this study
(Figure 3.4). TEC is an oily colorless, odorless liquid with molecular weight 276.3 g/mol
and density 1.135 g/cm3. The melting point is -55°C and boiling point is 294°C at 101.3
kPa. Triethyl citrate is an environmentally friendly, non-toxic material and its use is
permitted as food additive, and in the medical and pharmaceutical fields.

Figure 3.4 Chemical structure of triethyl citrate.

3.2 Sample Preparation

3.2.1 Preparation of Dapsone Functionalized Clay (DAP/Clay)
MMT-Na+ (2g) were first dispersed in 200ml distilled water with stirring for eight hours.
Dapsone (0.45g, 2x stoichiometric amount based on CEC) was ionized in 10ml 1.0N
hydrochloric acid and diluted with 50ml water. Ionized Dapsone solution was added
dropwise into the MMT-Na+ suspension within one hour. It is to be noted that the initial
pH value of 1.7 of the ionized dapsone solution increased to 2.0 after mixing with the
clay suspension for one hour. The reacted suspension was then filtered through a Buchner
funnel and the cake was washed with distilled water twice to eliminate the excess API.
Finally, the products were dried at 60oC for fifteen hours and 80oC for five hours and
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ground with mortar and pestle to obtain fine powders. Different experimental conditions
were also used and investigated in the intercalation study (Appendix C).
3.2.2 Preparation of Eudragit® S-100/DAP, and Eudragit® S-100/DAP/Clay
Compounds by Melt Mixing
Eudragit® S-100 was premixed with 20wt% TEC in a wrist action shaker (Burrell
Corporation, Pittsburgh, PA) for 12h. 10wt% DAP, 10wt% DAP modified clay and
10wt% of a DAP/Clay physical mixture were melt compounded with the premix in the
batch mixer (PL2000, C. W. Brabender) at 50 rpm and 160oC for 3 minutes. After melt
mixing, the samples were pressed into thin disks for further characterization.

3.3 Characterization

3.3.1 Fourier Transform-Infrared (FT-IR) Spectroscopy
FT-IR spectra were obtained on Spectrum One FT-IR Spectrometer® (Perkin Elmer
Instruments) using the KBr pellet method. Samples (1wt%) were mixed with dry
potassium bromide powder and compressed to 13mm discs by a torque wrench. Each disc
was scanned 25 times over the mid infrared range wavelength 400-4000 cm-1. The
evaluation was carried out with the Spectrum v3.02 program.
3.3.2 Wide Angle X-Ray Diffraction (WXRD)
Wide angle X-Ray diffraction analysis was performed using a Philips PW-3040
diffractometer with Cu target and Kα radiation (λ=0.154 nm) at 45kV/40mA. All
specimens were scanned in the 2θ range from 2°-40° at a rate of 0.003°/sec. The
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interlayer spacings of unmodified and API modified clays were calculated using Bragg’s
law of diffraction (Equation 3.1):

2d 

n
sin 

(3.1)

Where n=1 in this case, λ is the wavelength of the incident X-ray beam in Å, and θ is the
angle of incidence in degrees.
3.3.3 Thermogravimetric Analysis (TGA)
Thermogravimetric analysis (TGA) was performed using TGA Q-50 themogravimetric
analyzer (TA Instruments) in a ramp from room temperature to 500°C. Samples were
placed in an open aluminum pan and heated at a rate of 10°C/min in nitrogen atmosphere
(flow rate 40 cm3/min).
3.3.4 Differential Scanning Calorimetry (DSC)
Glass transition temperatures (Tg) and melting temperatures (Tm) were determined by
differential scanning calorimetry (DSC Q-100, TA instruments). Each sample was
analyzed at heating and cooling rates of 20°C/min, over a predetermined temperature
range under 40 cm3/min nitrogen flow rate.
3.3.5 Scanning Electron Microscopy (SEM)
The fracture surfaces of polymer compounds were examined by Scanning Electron
Microscopy (LEO 1530 VP Emission SEM) at 3-5 keV working voltage.
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3.3.6 Energy Dispersive X-Ray Analysis (EDX)
To quantitatively analyze the dispersion of API and clay in the polymer matrix, Energy
Dispersive X-ray analysis (EDX) (2400 Perkin-Elmer Elemental Mapping) was used.
Elemental mappings made it possible to identify major characteristic elements present on
the surface and to determine their distribution. The working voltage was 5 kV and
mapping time was 300 seconds for all species.
3.3.7 Elemental Analysis
Elemental analysis was performed by the QTI Laboratories, NJ, USA. Perkin-Elmer 2400
Elemental Analyzer was used for determination of carbon, hydrogen, and nitrogen
content in the API modified clay. The nitrogen content was then used for calculating the
API content in the nanoclay, since the nanoclay does not contain nitrogen.
3.3.8 Dissolution Test and UV-Vis Analysis
Drug dissolution was studied in a Distek dissolution system 2100A with a Distek
temperature control system TCS 0200. Eudragit® S-100 compounds with API and
API/clay hybrid were compressed into 2mm disks having the same holder geometry
(circular). The dissolution medium (1L), pH 7.4 phosphate buffer solution simulated the
colonic fluid and was maintained at 37±0.5°C with paddle rotation speed of 100rpm. 5ml
samples were withdrawn at predetermined time intervals. After filtration through a
0.45µm filter, API concentration was analyzed at 295nm by UV-Vis spectrophotometer
(Evolution 60, Thermo Scientific). The experiments were repeated three times.

CHAPTER 4
DISCUSSION

4.1 Results on Clay Modified with Dapsone
4.1.1 FTIR Analysis
FTIR spectra of Dapsone, MMT-DAP, and MMT-Na+ are shown in Figure 4.1. In the IR
spectrum of MMT-Na+, the characteristic band at 803 cm-1 indicates the platy structure of
montmorillonite.35 The peaks at 3632 cm-1 and 3447 cm-1 are the characteristic stretching
vibrations of the O-H bonds in Al-OH and absorbed water in the layers. The peak at 1649
cm-1 is attributed to the O-H bending vibration. The absorption bands at 1045 cm-1 and
917 cm-1 are the Si-O stretching (in-plane) vibration and the Al-Al-OH bending vibration
in the octahedral layer respectively.36 The Si-O bending vibration appears at 529 cm-1.
In the spectrum of Dapsone, the strong stretching vibration of the sulfone group
O=S=O is at 1108 cm-1 and the bending (out-of-plane) vibration of p-disubstituted
aromatic ring at 831 cm-1. The peaks at 1598 cm-1 and 3367 cm-1 correspond to the N-H
bending vibration and stretching vibration respectively.37 In the spectrum of MMT-DAP
hybrid, the characteristic peaks at 529 cm-1, 803 cm-1 and 1045 cm-1 were the same as
those of the sodium montmorillonite; the other newly created peaks can be ascribed to
surface coated and/or intercalated Dapsone. The absorption band due to the (O=S=O)
stretching vibration became weak and shifted to 1112 cm-1 in the hybrid. Similarly, the
peaks of N-H and p-disubstituted aromatic ring bending vibrations shifted to 1611 cm-1
and 847 cm-1 and both weakened. Compared with the spectra of MMT-Na+ and Dapsone,
the new absorption band at 3412 cm-1 may be due to the amine group forming chemical
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bonds with montmorillonite. The changes taking place in the IR spectrum of the MMTDAP hybrid indicate that Dapsone is not only attached on the surface but also intercalated
in the aluminosilicate layers of montmorillonite.

Figure 4.1 FTIR results of (a) Dapsone (DAP), (b) MMT-DAP, and (c) MMT-Na+.

4.1.2 XRD Analysis
XRD analysis was used to determine the structural geometry and evaluate the effect of
intercalation of Dapsone into the interlayers of montmorillonite. From Figure 4.2,
Dapsone appears as a highly crystalline structure containing many sharp peaks. Two
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sharp peaks in the MMT-Na+ XRD pattern are related to the planes (001) and (002) of
montmorillonite35. MMT-Na+ exhibits a strong peak around 7.53°indicating its original
basal spacing (d001) is 1.17nm; the peak shifted to 5.69°in the X-ray diffraction profile of
the MMT-DAP hybrid corresponding to an increased interlayer spacing (d001) of 1.55nm.
This is attributed to the intercalation of Dapsone into the clay interlayer space. The planes
(002) of montmorillonite sodium were not affected during the formation of the hybrid.

Figure 4.2 XRD results of (a) Dapsone, (b) MMT-Na+, and (c) MMT-DAP.
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4.1.3 Thermal Analysis
TGA data of MMT-Na+, MMT-DAP and Dapsone are shown in Figure 4.3. Dapsone is
thermally stable and started decomposing around 300°C. For MMT-Na+ and MMT-DAP,
the weight loss below 150°C is attributed to the evaporation of adsorbed water. At higher
temperature, MMT-Na+ does not show weight loss, but MMT-DAP shows a similar
pattern of weight loss as compared to the thermal decomposition of Dapsone in the region
of 250-500°C. According to the TGA analysis, after subtracting the moisture content of
the MMT-DAP, the approximately 7% additional weight loss could be attributed to the
weight of both intercalated and coated Dapsone.

Figure 4.3 TGA results of (a) MMT-Na+, (b) MMT-DAP, and (c) Dapsone.
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The DSC results (Figure 4.4) show that Dapsone has one strong endothermic peak
at 178°C corresponding to its melting point. MMT-Na+ does not show any peak, similarly
to the MMT-DAP hybrid. This may suggest the presence of intercalated and/or coated
Dapsone in an amorphous state.

Figure 4.4 DSC results of MMT-Na+, MMT-DAP, and Dapsone.

4.1.4 Quantitative Analysis of MMT-DAP
The API loading of MMT-DAP was determined by elemental analysis. Nitrogen is a
unique element present only in the API. Therefore, by using this information, the content
of Dapsone in the clay can be readily calculated (Appendix A). The calculations based on
stoichiometric CEC of MMT-Na+ indicate that 10.31% Dapsone can be loaded on the
clay theoretically; however, from the results of nitrogen elemental analysis, the calculated
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Dapsone loading in MMT-DAP is 12.32%. The 2% difference may due to Dapsone
coating the clay surface.
Table 4.1 Results of MMT-DAP Elemental Analysis
Material
MMT-DAP

% Carbon
7.08

% Hydrogen
2.05

% Nitrogen
1.39

4.1.5 Dissolution Test
Figure 4.5 shows the percentage of dissolved API from Dapsone and MMT-DAP as a
function of time in a phosphate buffer (pH=7.4). Dapsone shows a slow dissolution
profile, by comparison to the much faster dissolution profile in gastric fluid (pH=1.2).

Figure 4.5 Dissolution results in simulated intestinal fluid (phosphate buffer pH=7.4) of
(a) Dapsone and (b) MMT-DAP.
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MMT-DAP hybrid shows a fast release rate in the first 30 minutes, which is
probably due to the rapid release of Dapsone coating the clay surface and its fast
dissolution in an ionized form. After 30 minutes, the release rate of Dapsone from MMTDAP slowed down indicating that the release of the API from the interspacing was
dominant. The hybrid also increased the apparent solubility of Dapsone, possibly because
the API was present in an ionized and/or amorphous state.

4.2 Results on API Compounded with Eudragit®S100
4.2.1 Thermal Analysis
Figure 4.6 shows TGA results of the API, Eudragit®S100, plasticizer and blends
containing the plasticizer and API. The decreased weight loss of TEC at 130°C was due
to volatilization and possible decomposition. Eudragit®S100 without plasticizer had an
initial weight loss at 180°C and began to decompose at 370°C. The polymer combined
with TEC started losing 20wt% at 130°C. Due to processing difficulties at low
temperatures, 160°C was selected as the compounding temperature; also, the expected
evaporation loss could reduce the concentration of TEC in the polymer to a lower value.
After hot-melt mixing with the API, the TG analysis indicates the higher API
concentration in the polymer matrix could increase the thermal stability of the blend,
which could be mainly due to the presence of the more thermally stable Dapsone.
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Figure 4.6 TGA results of (a) Dapsone, (b) Eudragit ®S100, (c) TEC, (d) Eudragit®S100/
20wt% TEC, (e) Eudragit®S100/ 20wt% TEC-5wt% DAP, and (f) Eudragit®S100/
20wt% TEC-10wt% DAP.
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Figure 4.7 Tg of (a) Eudragit®S100, (b) Eudragit®S100/ 20wt% TEC, (c) Eudragit®S100/
20wt% TEC-5wt% DAP, and (d) Eudragit®S100/ 20wt% TEC-10wt% DAP.

In Figure 4.7, the Tg of the DAP-polymer blends decreased with increasing API
loadings. Generally, in amorphous miscible systems, the presence of the smaller API
molecules can dilute and weaken the cohesive interactions between the polymer chains.
This can enhance the molecular mobility of polymer chains by increasing the free volume
in the polymer matrix.21
4.2.2 XRD Analysis
Figure 4.8 shows XRD results of Dapsone and Eudragit®S100/DAP composites. As
discussed before, the Dapsone spectrum suggests a high degree of crystallinity. When
compared with plasticized Eudragit®S100, besides a peak around 2 = 13°, the APIpolymer blends do not show other crystalline peaks. The single peak was considered as
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an indication of impurity in the Dapsone raw material, which was further confirmed by
polarized microscopy. Therefore, it is evident that after hot-melt mixing Dapsone is
present in an amorphous state in the polymer matrix.

Figure 4.8 XRD results of (a) Eudragit®S100/ 20wt% TEC, (b) Eudragit®S100/ 20wt%
TEC-10wt% DAP, (c) Eudragit®S100/ 20wt% TEC-5wt% DAP, and (d) Dapsone.

4.2.3 Morphology
Polarized light microscopy, SEM images and EDX sulfur mapping confirmed the absence
of crystalline particles and the uniform distribution of a fully dissolved Dapsone in the
polymer matrix.
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Figure 4.9 Polarized optical microscopy image of Eudragit®S100/ 20wt% TEC-10wt%
DAP.

Figure 4.10 SEM image of Eudragit®S100/ 20wt% TEC-10wt% DAP (left) and EDX
sulfur mapping image of the same region (right).

According to the supplier’s specifications, 97% purity Dapsone was used in this
study, and by comparing with its X-ray diffraction profile, the particles observed in
Figure 4.9 are concluded to be impurities. From the SEM image, the entire surface is
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quite smooth and the EDX sulfur mapping (Figure 4.10) further confirms that Dapsone
was fully dissolved in the polymer matrix.
4.2.4 Dissolution Test

Figure 4.11 Dissolution results in simulated intestinal fluid (phosphate buffer pH=7.4) of
(a) Dapsone, (b) Eudragit®S100/ 20wt% TEC-5wt% DAP and (c) Eudragit®S100/ 20wt%
TEC-10wt% DAP.

Figure 4.11 shows the dissolution profiles of Dapsone and Eudragit®S100 blends in
phosphate buffer solution. The API-polymer blends showed zero-order release profiles,
and the release rate increased with increasing API loading. The TEC content in the tablets
can increase the API release rate due to the leaching of the water soluble plasticizer
during the dissolution test, leading to channel formation in the tablets. Also, during the
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dissolution process at pH 7.4, the carboxylic groups in the polymer are ionized and can
interact with the amine groups in the Dapsone molecule through ionic bond formation or
hydrogen bonding.38 It was hypothesized that following an increase in API loading, the
chemical and physical interactions between the functional groups of Eudragit®S100 and
Dapsone would also increase, resulting in higher release rate. Needless to mention that
the release rate also depends on the size and geometry of the hot-melt processed tablets.
In this dissolution test, 25 mm diameter and 2 mm thickness tablets were used and the
weight of each sample was 750±30 mg. On the basis of fully dissolved sample (c), after 7
hours, approximately 200 mg of sample (b) containing 5 wt% Dapsone still remained,
which further confirms the previous hypothesis. In addition to the favorable interactions
between molecules of API and polymer, the API’s increased solubility can be explained
based on the API’s amorphous state in the polymer matrix.
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4.3 Results on DAP Modified Clay Compounded with Eudragit®S100
4.3.1 Thermal Analysis
Figure 4.12 shows TGA results of Eudragit®S100 plasticized with 20 wt% TEC and of
the plasticized composites blended with Dapsone, DAP/MMT-Na+ physical mixture and
MMT-DAP hybrid.

Figure 4.12 TGA results of (a) Eudragit®S100/ 20wt% TEC, (b) Eudragit®S100/ 20wt%
TEC-10wt% DAP, (c) Eudragit®S100/ 20wt% TEC-10wt% (DAP/MMT-Na+ physical
mixture), and (d) Eudragit®S100/ 20wt% TEC-10wt% (MMT-DAP hybrid).

In samples (b), (c) and (d), the amount of additives were all 10 wt% based on the
amount of plasticized Eudragit®S100. Also, for comparison, the amount of Dapsone used
in the DAP/MMT-Na+ physical mixture was in the same proportion as that in the MMTDAP hybrid (12.32 wt%). Figure 4.12 indicates that adding the DAP/MMT-Na+ physical
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mixture and the MMT-DAP hybrid into the plasticized polymer can slightly reduce the
thermal stability, which is probably due to the layered structures of montmorillonite that
can catalyze the degradation of polymer matrices.39 Compared with the pristine sodium
montmorillonite, the average particle size of API modified clay is much larger, which
may be the reason of the lower thermal stability.

Figure 4.13 Tg of (a) Eudragit®S100, (b) Eudragit®S100/ 20wt% TEC-10wt% DAP, (c)
Eudragit®S100/ 20wt% TEC-10wt% (DAP/MMT-Na+ physical mixture), and (d)
Eudragit®S100/ 20wt% TEC-10wt% (MMT-DAP hybrid).

Figure 4.13 shows the glass transition temperature values of the corresponding
samples. Samples (c) and (d) appear to have higher glass transition temperatures than
sample (b) as a result of the presence of the nanoclay that could decrease the free volume
of the polymer matrix.
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4.3.2 XRD Analysis
Figure 4.14 shows the XRD results of MMT-Na+, MMT-DAP, and 20 wt% TEC
plasticized Eudragit®S100 blended with Dapsone, DAP/MMT-Na+ physical mixture and
MMT-DAP.

Figure 4.14 XRD results of (a) Eudragit®S100/ 20wt% TEC-10wt% DAP, (b) MMT-Na+,
and (c) MMT-DAP, (d) Eudragit®S100/ 20wt% TEC-10wt% (MMT-DAP hybrid), and (e)
Eudragit®S100/ 20wt% TEC-10wt% (DAP/MMT-Na+ physical mixture).

Compared with the characteristic peaks of (b) MMT-Na+ and (c) MMT-DAP, the
d001 peaks in the profiles of samples (d) and (e) both shifted to a lower angle indicating
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that the interspacing of montmorillonite was extended after hot-melt processing. During
melt mixing, the polymer chains could penetrate the interlayers of the clay and expanded
the spacing. For the XRD profile of sample (d), the weak peak intensity may be due to
the presence of Dapsone molecules in the interspacing obstructing the intercalation of
polymer chains into the layered structure.
4.3.3 Morphology
Sulfur is one of the unique elements present only in the API and is readily detected by
EDX. Figure 4.15 shows a facture surface of the Eudragit® S100 composite containing
20wt% TEC and 10wt% DAP/MMT-Na+ physical mixture, and the EDX mappings of
elements aluminum, silicon, sodium and sulfur. From EDX analysis, API and clay
particles are uniformly dispersed in the Eudragit® S100 matrix. One of the areas
containing large particles is magnified in Figure 4.16 and Figure 4.17. The layered
structures shown in Figure 4.17 indicate the agglomeration of the clay. The images of
EDX mapping of aluminum (left) and silicon (right) in Figure 4.16 further confirm the
location of montmorillonite agglomerates.
Figure 4.18 shows an SEM image of 10wt% MMT-DAP hybrid in plasticized
Eudragit® S100 composites, and the corresponding EDX mappings of elements
aluminum, silicon and sulfur. By rough approximation from the SEM image, the particles
have a wide range of distribution (10µm - 90µm) due to the non-uniformity at the
grinding step after modification. Sodium was not detected by EDX and the higher
population of Al, Si and S overlapped with the larger particles shown in the SEM image,
which proved that in combining montmorillonite with Dapsone the sodium was replaced
by the API.
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Figure 4.15 SEM image of 10wt% DAP/MMT-Na+ physical mixture in Eudragit®S100
and EDX mappings of elements aluminum, silicon, sodium and sulfur.
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Figure 4.16 SEM image of 10wt% DAP/MMT-Na+ physical mixture in Eudragit®S100
and EXD Mapping of aluminum (left) and silicon (right).

39

Figure 4.17 Magnified SEM images of the circle shown in Figure 4.16.
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Figure 4.18 SEM image of 10wt% MMT-DAP hybrid in Eudragit® S100 and EDX
mappings of elements aluminum, silicon and sulfur.
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4.3.4 Dissolution Test

Figure 4.19 Dissolution results in simulated intestinal fluid (phosphate buffer pH=7.4) of
(a) Eudragit®S100/ 20wt% TEC-10wt% DAP, (b) Eudragit®S100/ 20wt% TEC-10wt%
(DAP/MMT-Na+ physical mixture), and (c) Eudragit®S100/ 20wt% TEC-10wt% (MMTDAP hybrid).

Figure 4.19 shows the dissolution profiles of plasticized Eudragit®S100 composites with
API, API-clay physical mixture and API-clay hybrid in phosphate buffer solution. As
discussed before, size and geometry of the tablets can affect the release rate. In order to
dissolve all samples within 7 hours, in this dissolution test 30 mm diameter and 1 mm
thickness tablets were used and the weight of each sample was 550±20 mg. The APIclay-polymer blends also show zero-order release profiles, and the release rate decreased
by adding clay. The montmorillonite platelets may act as a barrier to block the interaction
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between Dapsone and polymer functional groups and slow down the Dapsone release
process. The sample containing MMT-DAP hybrid shows the slowest release profile
since Dapsone was present in the clay interlayers, and it had to experience one more step
in its release path. However, this release behavior cannot achieve 100% dissolution of
API since the undissolved Dapsone may have been locked in the clay interspacing.

CHAPTER 5
CONCLUSIONS

A cationic nanoclay, sodium montmorillonite, was successfully intercalated by Dapsone.
According to the experiments, the intercalation through ion exchange between ionized
Dapsone and MMT-Na+ is a fast process. This may be attributed to the linear chemical
structure of Dapsone which can pass through the interlayers of montmorillonite with a
relative ease. Temperature and soaking time did not have a significant effect on the
modification indicating that the interaction between the Dapsone molecules and the
aluminosilicate layers of montmorillonite is effective and strong. According to the XRD
patterns, MMT-DAP showed an increased interlayer spacing by comparing with the
results of untreated MMT-Na+ due to being Dapsone intercalated into the clay interlayer
space. By contrast to the pure Dapsone having high crystallinity, the API exists in an
amorphous state in the hybrid. Also, the amount of intercalated API depends on the
cation exchange capacity of the clay. In simulated intestinal fluid, sustained API release
from MMT-DAP can also be an indication of intercalated API, whereas fast release at the
initial stage was due to the presence of Dapsone coating on the clay. The delayed release
of Dapsone in a second stage indicates that the release of the API from the interspacing
was dominant.
In a separate part of this work, Eudragit®S100 was melt compounded with
Dapsone at 5 wt% and 10 wt% loadings. Consistent with the anticipated miscibility based
on calculated solubility parameter differences, a miscible system was obtained with
Dapsone present in an amorphous state in the polymer matrix. Compared with the high Tg
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of Eudragit®S100, the polymer/API blends had lower glass transition temperature and
increasing thermal stability with increasing Dapsone loading. The presence of the
thermally stable Dapsone can enhance the molecular mobility of polymer chains by
increasing the free volume in the polymer matrix. The increased apparent solubility of
Dapsone from Eudragit®S100/Dapsone blends in pH 7.4 buffer solution was mainly
attributed to the favorable interactions between molecules of the API and polymer. The
water soluble plasticizer can also result in higher release rate of Dapsone.
API modified clay was melt mixed with Eudragit®S100 forming a ternary system.
By contrast to the binary polymer/API system, the ternary system has higher glass
transition temperature and lower thermal stability, perhaps because of the catalytic effect
of montmorillonite on the polymer degradation. Use of this ternary system could decrease
the release rate as well as increase the apparent solubility of the API in pH 7.4 buffer
solution. The presence of nanoclay in the polymer matrix provided one more tortuous
API diffusion path to lower the release rate.
In future studies, it would be of interest to identify the different effects of melt
mixing by twin screw extrusion and batch mixer on Eudragit®S100/DAP and
Eudragit®S100/MMT-DAP systems. Furthermore, except Dapsone, other cationic APIs
with different chemical structure may affect the rate of the intercalation with
montmorillonite and the release rate of APIs from the MMT interlayers. A novel
application may be possible by using two API/clay systems with different API release
rates mixed with a particular polymer, which is expected to achieve staged release.

APPENDIX A
CALCULATION OF API CONTENT IN NANOCLAY

According to elemental analysis, MMT-DAP contains 1.39 wt% of nitrogen. Every
Dapsone molecule has two nitrogen atoms, and the molecular weight of Dapsone is
248.302g/mol. Based on this information, the content of Dapsone in the clay can be
calculated.
Step 1. The percentage of nitrogen in Dapsone is:

% 

28.0134g/mol
 11.282%
248.302g/mol

Step 2. The content of Dapsone in MMT-DAP is:

Dapsone% 

1.39%
 12.32%
11.282%
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APPENDIX B
CALCULATION OF SOLUBILITY PARAMETERS

The calculation of solubility parameters using the group contribution method is shown
below. In the following Tables the symbols represent:
z = functional group
z

U = molar cohesive energy

z

V = molar volume

For Dapsone,
Table B.1 Hildebrand Solubility Parameters of Dapsone Groups
GROUP, z
2 Phenylene
2 (-NH2)
1 (-SO2-) 40

z

U/kJ∙mol-1
31.94
12.56
39.12
Total

∑ zU/kJ∙mol-1
63.88
25.12
39.12
128.12

z

V/cm3∙mol-1
52.4
19.2
23.6
Total

∑ zV/cm3∙mol-1
104.8
38.4
23.6
166.8

δ  ( ei /  vi )0.5  (128120 /166.8)0.5  27.7MPa1/2
For Eudragit® S100,
Table B.2 Hildebrand Solubility Parameters of Eudragit® S100 Groups
GROUP, z
3 (-CH3)
1 (-COO-)
3 (-CH2)
2 (C)
1 (-COOH)

z

U/kJ∙mol-1
4.71
18.0
4.94
1.47
27.63
Total

∑ zU/kJ∙mol-1
14.13
18.0
14.82
2.94
27.63
77.52

z

V/cm3∙mol-1
33.5
18.0
16.1
-19.2
28.5
Total

δ  ( ei /  vi )0.5  (77520 /156.9)0.5  22.2MPa1/2
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∑ zV/cm3∙mol-1
100.5
18.0
48.3
-38.4
28.5
156.9
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Compounds with similar values of solubility parameters are likely to be miscible.
This is because the energy of mixing within the components is balanced by the energy
released by interaction between the components21. Greenhalgh demonstrated that
compounds with δ<7.0MPa1/2 are likely to be miscible while compounds with
1/2
are likely to be immiscible.22
δ>10.0MPa


Following these guidelines, since the value for δ of Dapsone is calculated to be
27.7MPa1/2 and compared with the values for δ of Eudragit® S100, it can be predicted

that Eudragit® S100 with δ of 22.2MPa1/2 is likely to be miscible with the API. The
prediction was in agreement with the experimental results where Dapsone particles were
dispersed in an amorphous form in Eudragit® S100 after hot-melt mixing.

APPENDIX C
INTERCALATION STUDY

In order to achieve maximum intercalation of API into the interlayer of montmorillonite,
different experimental conditions were used. Effect of ionization of Dapsone, soaking
time, temperature and initial concentration of Dapsone were investigated.
The abbreviations of Dapsone modified MMT-Na+ obtained under different
cationic exchange conditions are shown in Table C.1.
Table C.1 Abbreviations of MMT-Na+ Samples Modified with Dapsone
Abbreviations
(a) 2xRT24h-N
(b) 2xRT24h
(c) 2xRT15h
(d) 2xRT3h
(e) 2xRT1h
(f) 2x60oC3h
(g) 2x60oC1h
(h) 1xRT1h

Exchange
Temperature
RT
RT
RT
RT
RT
60°C
60oC
RT

Soaking
Time
24h
24h
15h
3h
1h
3h
1h
1h

Ionization
−
√
√
√
√
√
√
√

API used amount
based on CEC
2x
2x
2x
2x
2x
2x
2x
1x

Effect of ionization of Dapsone
Considering that Dapsone is insoluble in neutral pH but its solubility increases in acidic
pH and it can dissolve in an organic solvent, two methods were used to identify the effect
of the medium of intercalation. The first method (sample (a)) is to dissolve Dapsone in
ethanol before clay modification, and the second method (sample (b)) is first to ionize
Dapsone with hydrochloric acid. Other ion exchange conditions are kept the same, i.e.,
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soaking time 24 hours with continuous stirring at room temperature, twice the
stoichiometric amount of API based on the CEC of the clay.
In the XRD analysis shown in Figure C.1, compared with the XRD profile of
pristine MMT-Na+, a peak at 2 of 5.69 for sample (b) corresponds to an increased
interspacing of 1.55nm and intercalation of Dapsone into the clay interlayer space. By
contrast, a peak at 2 of 8.77 for sample (a) shows that the interspacing shrunk to
1.07nm, an indication that ion exchange did not happen. The shrinkage of interspacing
may be attributed to the removed sodium ion in the MMT layers caused by the long
soaking time.

Figure C.1 XRD results of Dapsone, MMT-Na+, (a) 2xRT24h-N and (b) 2xRT24h.
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Figure C.2 TGA results of Dapsone, MMT-Na+, (a) 2xRT24h-N and (b) 2xRT24h.
The TGA results further indicate that un-ionized Dapsone is not present in the
hybrid. In Figure C.2, in the temperature range of 250°C to 500°C, the expected weight
loss not appears in sample (a). According to sample (b), the weight loss after 250°C can
be ascribed to the Dapsone loaded in the clay. These results suggest that ionization of
Dapsone for the ion exchange reaction is necessary.

Effect of soaking time on the intercalation
Ionized Dapsone solution (2x stoichiometric amount based on CEC) was added into
200ml of well dispersed MMT (2g) suspension with continuous stirring at room
temperature for 1h, 3h, 15h, and 24h, respectively.
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Figure C.3 Weight loss of MMT-DAP hybrids soaked in different times.
The weight loss of API was calculated from TGA results (range 250°C to 500°C).
Figures C.3 and C.4 show that the intercalation of ionized Dapsone in MMT-Na+ is a fast
process and the soaking time effect on intercalation is negligible. However, it appears
that intercalation decreased with increasing soaking time. The major mechanisms of
Dapsone intercalation into montmorillonite are: (1) ionized Dapsone adsorbs onto the
surface of MMT-Na+; (2) ionized Dapsone replaces sodium ions and is present in the
basal spacing of the clay. The very rapid intercalation may be attributed to the linear
chemical structure of Dapsone which can then pass through interlayers of
montmorillonite with relative ease. Followed the time increasing, the intercalated
Dapsone could pass through the interspacing and re-coated onto the clay surface. After
washing and filtering, the surface Dapsone can be washed away, thus resulting in a
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decrease of API loading.

Also, since montmorillonite is unstable in very acidic

conditions interaction time was set to 1 hour and the Dapsone solution was added
dropwise into the clay suspension.

Figure C.4 XRD results of (b) 2xRT24h, (c) 2xRT15h, (d) 2xRT3h and (e) 2xRT1h.
Effect of temperature on intercalation
To study the effect of temperature in short soaking time, two groups of samples were
used. Group one contains sample (e) and sample (g) reacted for 1 h at room temperature
and 60°C, respectively. The second group contains sample (d) and sample (f) reacted for
3 h at room temperature and 60°C, respectively. The trends in Figure C.5 indicate that in
short intercalation times, higher temperature could decrease the API loading. High
temperature can affect rapid molecular motion of Dapsone during ion exchange leading
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to easier penetration of Dapsone molecules through clay interlayers, in which the API
ions are supposed to attach but finally will be filtered or washed away. However, the
temperature effect on intercalation is also not obvious. Figure C.6 shows the XRD data of
those four samples indicating that intercalation to different degrees took place in each
sample.

Figure C.5 Intercalation of Dapsone at different temperatures.
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Figure C.6 XRD results of (d) 2xRT3h, (e) 2xRT1h, (f) 2x60oC3h and (g) 2x60oC1h.

Figure C.7 TGA results of (e) 2xRT1h and (h) 1xRT1h.
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Effect of initial Dapsone concentration on intercalation
Based on the cation exchange capacity of montmorillonite, stoichiometric and twice the
stoichiometric amounts of Dapsone were used. From Figure C.7, the TGA result shows
that in one hour intercalation time, the API loading of sample (h) is less than the API
loading of sample (e). Therefore, twice the stoichiometric amount of Dapsone is needed
to eliminate incomplete intercalation.
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